Search Results

You are looking at 61 - 70 of 899 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Anthony J. Olszanski

're looking at patients with melanoma because it can upstage them.” “N” refers to the number of tumor-involved regional lymph nodes and presence of in-transit, satellite, or microsatellite metastases. These can be clinically detected (ie, identified by

Full access

Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus

Anisley Valenciaga, O. Hans Iwenofu, and Gabriel Tinoco

liver metastases seen in (A) right posterior hepatic lobe measuring 1.9 cm and (B) right inferior lobe measuring 1.1 cm (yellow arrows) while patient received olaratumab maintenance therapy 15 months after initial surgery. The patient was then

Full access

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Louis Burt Nabors, Jana Portnow, Manmeet Ahluwalia, Joachim Baehring, Henry Brem, Steven Brem, Nicholas Butowski, Jian L. Campian, Stephen W. Clark, Andrew J. Fabiano, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Craig Horbinski, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, Ian Robins, Jason Rockhill, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Lode J. Swinnen, Stephanie Weiss, Patrick Yung Wen, Nicole E. Willmarth, Mary Anne Bergman, and Susan D. Darlow

one or many brain metastases, and they may have a malignancy that is highly responsive or, alternatively, highly resistant to radiation therapy (RT) or chemotherapy. Because of this marked heterogeneity, the prognostic features and treatment options

Full access

Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer

Boshen Jiao, Yaw A. Nyame, Josh J. Carlson, Louis P. Garrison Jr, and Anirban Basu

diagnosis of metastatic disease), 23 and presence of visceral or bone metastases. Statistical Analysis Primary Analysis We conducted a retrospective difference-in-differences (DID) analysis to assess the differential utilization of AAP between

Full access

Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy

Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano

nodal metastases and distant metastases, and greater accuracy versus bone scan in the detection of bone metastases. 4 – 6 One retrospective study by Niikura et al 7 reported 97.4% sensitivity and 91.2% specificity for PET/CT imaging compared with 85

Full access

Prostate Cancer, Version 1.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho

. Most patients with castration-recurrent or -resistant prostate cancer (CRPC) die of bone metastases and related complications. The recently approved radium-223 is the first bone-targeting agent to demonstrate a survival benefit in these patients

Full access

CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience

Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams

-rank tests. Results: 60 female pts were included in this study. The median age was 59 years (24–78). 45 (75%) pts were postmenopausal, 44 (73%) ER+/PR+, 14 (23%) ER+/PR-, and 2 (3%) ER-PR-, 28 (47%) with only bone metastases, 19 (32%) with visceral and bone

Full access

Central Nervous System Cancers

Steven S. Brem, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Ennio A. Chiocca, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Larry Junck, Gerald P. Linette, Jay S. Loeffler, Moshe H. Maor, Madison Michael, Paul L. Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, Frank D. Vrionis, and Patrick Y. Wen

. Between 20% and 40% of patients with systemic cancer will develop brain metastases. 3 NOTE: This manuscript highlights only a portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Central Nervous System Cancers. Please refer

Full access

Experimental Therapies and Clinical Trials in Bone Sarcoma

Rashmi Chugh

, which is implicated in many cancers. 29 , 30 Bisphosphonates reduce osteolytic bone metastases in many cancers, including breast cancer, myeloma, and prostate cancer. 31 These effects may result from bisphosphonates' effect on osteoclasts, angiogenesis

Full access

Response to Anti–PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis

Douglas B. Johnson, Riyue Bao, Kristin K. Ancell, Anthony B. Daniels, Deborah Wallace, Jeffrey A. Sosman, and Jason J. Luke

metastases and 2 had prior therapies (see supplemental eAppendix 1 , available online with this article at ). Of these 5 patients, 1 had a complete response (CR; ongoing at 25.5 months), and no partial responses were observed (response rate, 20